B3GNT2 siRNA (Human)

SiRNA to inhibit B3GNT2 expression using RNA interference

Product Specifications

Product Name Alternative

B3GALT7; B3GNT1; UDP-GlcNAc:betaGal beta-1.3-N-acetylglucosaminyltransferase 2; BGnT-2; Beta-1.3-Gn-T2; Beta-1.3-N-acetylglucosaminyltransferase 2; Beta3Gn-T2; Beta-1.3-N-acetylglucosaminyltransferase 1; BGnT-1; Beta-1.3-Gn-T1; Beta3Gn-T1; Beta-1.3-galactosyltransferase 7; Beta-1.3-GalTase 7; Beta3Gal-T7; Beta3GalT7; b3Gal-T7; Beta-3-Gx-T7; UDP-Gal:beta-GlcNAc beta-1.3-galactosyltransferase 7; UDP-galactose:beta-N-acetylglucosamine beta-1.3-galactosyltransferase 7

Reactivity

Source

Synthetic

Applications

RNAi

Purity

> 97%

Form

Lyophilized powder

Components

We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human B3GNT2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.

Storage Conditions

Shipped at 4 °C. Store at -20 °C for one year.

Specificity

B3GNT2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

NCBI Gene Symbol

B3GNT2

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.